A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

Changhoon Yoo(Ulsan College), Dong Wan Seo(Dankook University), S S Lee(Ulsan College), Je Hyeong Kim(Korea Advanced Institute of Science and Technology), D H Park(Ulsan College), Jia-Lin Lee(Ulsan College), Dongjin Han(Ulsan College), Jenn-Jiang Hwang(Ulsan College), MH Kim(Pusan National University), T W Kim(Ulsan College), S K Lee(Ulsan College), J S Lee(Ulsan College)
British Journal of Cancer
October 13, 2009
10.1038/sj.bjc.6605374
Cited by 170

Related Papers

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
TIMP-2 Mediated Inhibition of Angiogenesis
|Cell|2003|510
Practice of endoscopy during COVID-19 pandemic: position statements of the Asian Pacific Society for Digestive Endoscopy (APSDE-COVID statements)
|Gut|2020|332
Autoimmune Chronic Pancreatitis
|The American Journal of Gastroenterology|2004|288
Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin.
|PubMed|2000|279